53
Participants
Start Date
October 10, 2020
Primary Completion Date
December 1, 2024
Study Completion Date
December 1, 2025
Abemaciclib
Abemaciclib 150mg orally twice a day
Letrozole
Letrozole 2.5mg orally once a day
Columbia University Medical Center, New York
SUNY Upstate Medical University, Syracuse
Abington Memorial Hospital, Willow Grove
Reading Hospital-McGlinn Cancer Institute, Reading
University of Virginia, Charlottesville
West Virginia University, Morgantown
Lewis Cancer & Research Pavilion, Savannah
UF Health Cancer Center, Gainesville
Advent Health - Orlando, Orlando
University of Miami - Sylvester Cancer Center, Miami
UT Health Tower, Miami
Sylvester Comprehensive Cancer Center-Lennar Foundation Medical Center, Coral Gables
Sylvester Comprehensive Cancer Center-Plantation, Plantation
Cleveland Clinic Florida, Weston
Sylevester Comprehensive Cancer Center-Deerfield Beach, Deerfield Beach
University of South Alabama Mitchell Cancer Center, Mobile
Baptist Healthcare System, Lexington
St. Joseph Mercy Hospital, Ann Arbor
University of Chicago, Chicago
Oklahoma Cancer Specialists and Research Institute, Tulsa
Baptist Health Center Lexington, Salt Lake City
Huntsman Cancer Institute, Salt Lake City
Alaska Women's Cancer Care, Anchorage
Smillow Cancer Care at Greenwich, Greenwich
Yale University, New Haven
Tufts Medical Center, Boston
University of Massachusetts, Worcester
Rutgers Cancer Institute of New Jersey, New Brunswick
Holy Name Medical Center, Teaneck
Eli Lilly and Company
INDUSTRY
Gynecologic Oncology Group
NETWORK